Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Q2 net loss widens to $62.6 million on one-time stock compensation

Mixed Impact 3 of 5 earnings Written later

Seaport Therapeutics reported second-quarter 2026 results with a net loss of $62.6 million, up from $15.1 million a year earlier. The company said the increase was mainly due to one-time, non-cash stock-based compensation tied to its May IPO, and it ended the quarter with $427.3 million in cash and investments, which it expects to fund operations into 2029.

Key points

  • Net loss was $62.6 million, or $1.78 per share, versus $15.1 million, or $6.40 per share, in Q2 2025.
  • General and administrative expenses rose to $41.2 million from $5.1 million, including $36.0 million of non-cash stock-based compensation.
  • Research and development expenses rose to $24.6 million from $13.4 million as GlyphAllo and GlyphAgo advanced into later-stage development.
  • The IPO raised $260.0 million in gross proceeds, and cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026.

The filing

CompanySeaport Therapeutics, Inc. (SPTX)
Form8-K, current report
Filed with the SECAug 3, 2026, 7:03 AM ET
Accession number0001193125-26-329528

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.